Van Emburgh et al. analysed the clonal evolution of CRCs during EGFR inhibitor treatment using ctDNA analysis and concluded that before therapy, several RAS mutant subclones co-existed in CRC cell populations, and that during EGFR blockade, the clonal composition of CRCs changed [102]. This evidence concerns the gene EGFR and colorectal carcinoma.